Due: July 10, 2025
The Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department, in its role as the Joint Science and Technology Office (JSTO) for Chemical and Biological Defense, hereinafter referred to as “JSTO,” seeks to develop technologies that temporarily upregulate the expression of endogenous Butyrylcholinesterase (BuChE) and demonstrate enhanced protection against Organophosphorus Nerve Agent (OPNA) intoxication through submission of an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA). Manufacturing needs to demonstrate the ability to provide sufficient material for conducting clinical trials.
Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.